Skip to main content

Table 1 Patient characteristics of patients with DIP OA at cohort entry

From: Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis

Patient characteristics at baseline visit csDMARD, n = 847 bDMARD, n = 72 Combination, n = 257 Past-use, n = 19 Never-use, n = 145
Mean age [years] (SD) 60.1 (9.9) 61.9 (10.5) 58.6 (10.6) 60.7 (9.9) 60.9 (10.1)
Female (%) 653 (77.1%) 60 (83.3%) 195 (75.9%) 13 (68.4%) 112 (77.2%)
Mean follow-up time [years] (SD) 3.9 (2.3) 3.4 (1.6) 3.4 (1.9) 2.8 (1.2) 4.3 (2.8)
Mean BMI (SD) 25.9 (4.9) 24.9 (4.0) 25.6 (5.8) 25.6 (2.3) 25.6 (4.5)
Missing (%) 152 (17.9%) 3 (4.2%) 9 (3.4%) 6 (31.6%) 58 (40.0%)
Median RA duration [years] (IQR) 5.3 (2.0–12.8) 11.2 (5.0–18.9) 8.0 (3.9–14.4) 6.5 (2.7–8.7) 6.9 (1.7–16.4)
Missing (%) 21 (2.5%) 3 (4.2%) 8 (3.0%) 1 (5.3%) 7 (4.8%)
RF negative (%) 275 (32.5%) 33 (45.8%) 77 (30.0%) 6 (31.6%) 53 (36.6%)
RF positive (%) 559 (66.0%) 36 (50.0%) 163 (63.4%) 10 (52.6%) 78 (53.8%)
Missing (%) 13 (1.5%) 3 (4.2%) 17 (6.6%) 3 (15.8%) 14 (9.7%)
Mean DAS28-esra (SD) 4.0 (1.5) 4.1 (1.3) 3.9 (1.5) 3.7 (1.8) 4.4 (1.4)
Missing (%) 44 (5.2%) 1 (1.4%) 13 (5.1%) 4 (21.1%) 37 (25.6%)
≥ 365 days of current csDMARD useb (%) 281 (33.2%) 0 129 (50.2%) 0 0
≥ 365 days of current bDMARD usec (%) 0 18 (25.0%) 56 (21.8%) 0 0
Prednisone used (%) 443 (52.3%) 37 (51.4%) 147 (57.2%) 10 (52.6%) 62 (42.8%)
Cardiac disorderse (%) 80 (9.5%) 12 (16.7%) 25 (9.7%) 7 (36.8%) 10 (6.9%)
Hypertensionf (%) 206 (24.3%) 27 (37.5%) 52 (20.2%) 4 (21.1%) 37 (25.5%)
Osteoporosis or fractureg (%) 106 (12.5%) 27 (37.5%) 76 (29.6%) 1 (5.3%) 16 (11.0%)
Large joint osteoarthritish (%) 82 (9.7%) 9 (12.5%) 45 (17.5%) 5 (26.3%) 17 (11.7%)
Hand surgery (%) 67 (7.9%) 15 (20.8%) 33 (12.8%) 1 (5.3%) 12 (8.3%)
  1. DIP OA distal interphalangeal joint osteoarthritis, bDMARD biologic disease-modifying antirheumatic drug, BMI body mass index, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS Disease Activity Score, esr erythrocyte sedimentation rate, IQR interquartile range, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation
  2. aDAS28-esr = (0.56 × √[TJC28] + 0.28 × √[SJC28] + 0.70 × ln[ESR]) × 1.08 + 0.16
  3. bcsDMARD use includes methotrexate, leflunomid, sulfasalazin, chloroquine, azathioprine, cyclosporin A, and cyclophosphamid
  4. cbDMARD use includes abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab
  5. dPrednisone use includes systemic or intra-articular prednisone use
  6. eCardiac disorders include angina pectoris, myocardial infarction, arrhythmias, ischemic heart failure, angioplasty, or their treatment
  7. fHypertension includes also anti-hypertensive treatment
  8. gOsteoporosis or fractures include also anti-osteoporotic treatment
  9. hLarge joint osteoarthritis includes hip/knee replacements